International Journal of Hematology

DOI: 10.1007/s12185-017-2371-5 Pages: 1-6

ETV6–ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia

1. Kobe Children’s Hospital, Department of Hematology and Oncology, Children’s Cancer Center

2. Kobe University, Graduate School of Medicine, Department of Pediatrics

3. Hamamatsu University School of Medicine, Department of Pediatrics

4. Kobe University Hospital, Division of Clinical Laboratory

Correspondence to:
Suguru Uemura
Tel: +81-78-382-5111



ETV6–ABL1 fusion is a rare but recurrent oncogenic lesion found in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), without an established chromosomal abnormality, and is associated with poor outcome. In ETV6ABL1-positive cases, an in-frame fusion produced by a complex rearrangement results in constitutive chimeric tyrosine kinase activity. Monosomy 7 is also a rare and unfavorable chromosomal abnormality in childhood BCP-ALL. Here, we report a 14-year-old female BCP-ALL patient with ETV6–ABL1 fusion combined with monosomy 7. She was admitted to our hospital because of persistent fever. Bone marrow nuclear cell count on admission was 855,000/µL with 90.0% blastic cells of lymphoid morphology. Blasts were positive for CD10, CD19, CD20, CD34, cyCD79a, cyTdT, HLA-DR, and CD66c, had a karyotype of 45, XX, − 7 [18/20] and a split signal for ABL1 FISH probe (92.7%), and were sensitive to tyrosine kinase inhibitors, imatinib and dasatinib, in vitro. ETV6ABL1 fusion transcript was identified by whole transcriptome sequencing and confirmed by RT-PCR. She was treated with the high-risk protocol based on ALL-BFM 95, achieved complete remission (CR) after induction chemotherapy, and maintained CR for 4 months. To our knowledge, this is the first report of ETV6–ABL1 fusion combined with monosomy 7 in childhood BCP-ALL.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge